Ketamine and Depression: Antidepressant Mechanisms Revealed

Home
BLOG
Ketamine and Depression: Antidepressant Mechanisms Revealed

Clinician-scientists from Inserm, CNRS, the Sorbonne, AP-HP, and the Institut de Recherche en Brain de Paris have identified one mechanism that explains ketamine’s effect as an antidepressant. Ketamine, normally used as an anesthetic, was administered to patients with severe resistant depression.

The treatment increased patients’ ability to overcome negative beliefs about themselves and the world when researchers presented them with positive information. these results, published in JAMA Psychiatry, open new therapeutic avenues for the management of antidepressant-resistant mood disorders.

Depression is the most common psychiatric disorder, with an estimated 5-15% of French people experiencing a major depressive episode during their lifetime. All age groups and all social backgrounds are affected.

The illness is characterized by sadness and loss of pleasant emotions that are not ameliorated by positive events. Depressed patients develop negative thoughts about themselves, the world, and the future, which may develop into suicidal ideation. These negative beliefs remain even when the patient receives positive information.

About one-third of depressed patients do not respond to the most commonly prescribed antidepressants and are diagnosed with treatment-resistant depression (TRD). For these individuals, finding new and effective treatments is a priority.

Ketamine, a commonly used anesthetic, has been shown to affect resistant depression. While conventional antidepressant treatment takes time to take effect (an average of three weeks), ketamine has a rapid-acting antidepressant effect that occurs only hours after administration. The mechanisms associated with this rapid antidepressant effect are not yet known.

To elucidate these mechanisms, a research team led by Drs. Hugo Bottemanne and Philippe Fossati and Liane Schmidt (Inserm Research Fellow) at the Paris Brain Institute coordinated a clinical study of 26 antidepressant-resistant patients (TRD) and 30 healthy controls. The team coordinated a clinical study of 26 antidepressant-resistant patients (TRD) and 30 healthy controls.

In the protocol, patients and healthy controls were first asked to estimate the probability of 40 possible “negative” events in their lives (car accident, cancer, loss of wallet, etc.).

After being informed about the actual risk of occurrence in the general population, patients and healthy individuals were again asked to estimate the probability of these events occurring in their lives. The research team was interested in updating their beliefs after receiving the information. The results showed that healthy individuals tended to update their initial beliefs more after receiving positive, factual information, but this was not the case in the depressed patient population.

In this study, TRD patients were given ketamine in subanesthetic doses (0.5 mg/kg, 40 minutes) three times a week. Just 4 hours after the first dose, patients showed an increased ability to update their beliefs after receiving positive information. In addition, their sensitivity to negative information decreased and their ability to update their knowledge recovered to a level comparable to that of the control group.

Furthermore, improvement in depressive symptoms after ketamine administration was associated with these changes in belief updating, suggesting a link between clinical improvement and changes in this cognitive mechanism. In other words, the greater the patient’s ability to update beliefs, the greater the improvement in symptoms.

In conclusion, in this study, patients with antidepressant-resistant depression showed a significant decrease in symptoms and became more accepting of “positive” experiences after one week of ketamine treatment.

This study reveals for the first time the cognitive mechanisms potentially involved in the initial effects of ketamine. This paves the way for new research on antidepressant therapies that modulate mechanisms of belief renewal.

Read also

Brain scans prior to antidepressant treatment may predict response

Functional magnetic resonance imaging of the brain may help predict which patients will respond favorably to antidepressant treatment, according to a study published in the journal Brain. Researchers from the University of Illinois at Chicago and the University of Michigan conducted fMRI scans of patients with major depressive disorder who were about to begin antidepressant […]

Two common Antidepressants found safe for most stroke survivors.

Most stroke survivors could safely take two common antidepressants, according to a preliminary study to be presented at the American Stroke Association’s International Stroke Conference 2024. The conference will be held February 7-9 in Phoenix. Among ischemic (blood clot-causing) stroke patients who were started on antidepressants known as SSRIs (selective serotonin reuptake inhibitors) and/or SNRIs […]

Reactive Depression – How to Treat It and What Is It

When people talk about depression, they are usually referring to major depressive disorder, which affects about 21 million adults in the United States. This mental disorder affects a person’s thinking, mood, and behavior. It is characterized by lethargy, anxiety, anger, guilt, changes in eating and sleeping habits, and suicidal thoughts. However, such a diagnosis is […]

Why natural treatments for depression are better than drugs.

Winter is here. With it, depressive symptoms worsen each year. Sadly, suicide continues to claim more lives than firearms in the United States, and suicide rates are increasing in nearly every state. The Centers for Disease Control and Prevention reports that deaths by suicide have increased 30% since 1999, and similar trends are seen in […]

Venlafaxine Use in the Elderly in Relation to Markers of Bone Metabolism

Treatment of depression with venlafaxine is associated with increased levels of C-terminal cross-linked telopeptide (CTX) of type 1 collagen, a bone resorption marker, and decreased levels of N-propeptide (P1NP) of type 1 procollagen, a bone formation marker, according to a May 26 report in the Journal of the American Geriatrics Society, published online in the […]

Researchers identify subtype of depression using surveys, brain imaging and cognitive tests.

Researchers at Stanford Medical School conducted a study in which they described a new category of depression called the cognitive biotype, which accounts for 27% of depressed patients and is not effectively treated with commonly prescribed antidepressants. Cognitive tasks have shown that these patients have difficulty with the ability to plan for the future, exercise […]

Updated guidelines recommend second-generation antidepressants for the treatment of major depressive disorder in adults

The American College of Physicians (ACP) has published updated guidelines outlining clinical recommendations for nonpharmacologic and pharmacologic treatment of adults in the acute phase of major depressive disorder (MDD). In the updated clinical guidelines, ACP recommends the use of cognitive behavioral therapy (CBT) or second-generation antidepressants (SSRIs) as initial treatment for adults with moderate to […]

Economic Stress Linked to Worsening Biological Health, Study Finds

People who experience stressful life events and situations are more likely to have poorer biological health, according to a new study by UCL researchers, as indicated by biomarkers related to the interaction of the immune, nervous, and endocrine systems. The study, published in the journal Brain, Behavior and Immunity, found that not only major stress […]

The Efficacy and Side Effects of Antidepressants in the Treatment of Major Depressive Disorder: A Systematic Review and Meta-Analysis.

Antidepressants in the Treatment of Major Depressive Disorder What is the efficacy of antidepressants in treating major depressive disorder? Antidepressants are common prescription medications used to treat major depressive disorder and other conditions. Antidepressants have been shown to be effective in treating depressive symptoms and may be more effective than other medications in some individuals. […]

Popular pain medications carry a high risk of hypoglycemia.

Since its approval in 1995, the opioid tramadol (sold under the names Conzip and Ultram) has become widely prescribed for the treatment of osteoarthritis and other painful conditions, in part because of its lower risk of some side effects and lower potential for abuse than other opioids. It has become a popular drug. It is […]